18:38 , Feb 5, 2019 |  BC Extra  |  Company News

Management tracks: Amazon-Berkshire Hathaway-JPM venture hires Kutan as CTO

Serkan Kutan started in January as the CTO of the healthcare venture from J.P. Morgan (NYSE:JPM), Berkshire Hathaway Inc. (NYSE:BRK-A; NYSE:BRK-B) and Amazon.com Inc. (NASDAQ:AMZN). He was CTO of Zocdoc Inc. (New York, N.Y.), a...
00:47 , Feb 1, 2019 |  BC Week In Review  |  Company News

AbbVie loses $8B in market cap on steeper Humira erosion

AbbVie Inc. (NYSE:ABBV) lost $5.34 to $80.54 on Jan. 25, representing a loss of almost $8 billion in market cap, after announcing it expects a higher rate of erosion in ex-U.S. sales on autoimmune drug...
22:32 , Jan 25, 2019 |  BC Extra  |  Company News

AbbVie loses $8B in market cap on steeper Humira erosion

AbbVie Inc. (NYSE:ABBV) lost $5.34 to $80.54 on Friday, representing a loss of almost $8 billion in market cap, after announcing it expects a higher rate of erosion in ex-U.S. sales on autoimmune drug Humira...
01:15 , Jan 12, 2019 |  BioCentury  |  Finance

JPM jump-starts 2019

About three quarters of the more than 200 biopharma companies presenting at the 2019 J.P. Morgan Healthcare Conference saw their stock prices rise last week. Leading the pack was the 53% jump by Insmed Inc....
01:03 , Jan 12, 2019 |  BioCentury  |  Finance

Warning: cash needed

  A near decade-long run of cheap money appears to be coming to a close, and most of the biotech sector isn’t well positioned for the new reality. BioCentury’s analysis shows that two-thirds of biotech...
00:23 , Jan 12, 2019 |  BioCentury  |  Finance

We all fall down

After an exuberant third quarter that put biotech indexes near their 2015 highs, all market cap tiers fell in 4Q18, eliminating the first nine month’s gains and losing $291.2 billion in aggregate value. Median losses...
00:19 , Jan 3, 2019 |  BC Extra  |  Company News

Management tracks: Portola, Coherus

Hematology company Portola Pharmaceuticals Inc. (NASDAQ:PTLA) said SVP and CMO John Lawrence has resigned to pursue a new position with an undisclosed pharma company. Coherus BioSciences Inc. (NASDAQ:CHRS) hired Darlene Horton as chief medical and...
21:26 , Dec 4, 2018 |  BC Extra  |  Politics & Policy

Biosimilar makers back Pfizer in call to end misleading brand marketing

A group of biosimilar manufacturers including Pfizer Inc. (NYSE:PFE) urged FDA to produce supplemental guidance clarifying how to comply with existing law when communicating about biosimilars. The Biosimilars Forum sent its plea in a letter...
17:31 , Nov 9, 2018 |  BC Week In Review  |  Clinical News

FDA approves AcelRx, Coherus, Pfizer Products, rebuffs Trevena's Olinvo

FDA approved products from Coherus Biosciences Inc. (NASDAQ:CHRS), AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX) and Pfizer Inc. (NYSE:PFE) on Nov. 2, but issued a complete response letter to an NDA from Trevena Inc. (NASDAQ:TRVN). Coherus was up...
21:15 , Nov 2, 2018 |  BC Extra  |  Company News

FDA approves AcelRx, Coherus, Pfizer products, rebuffs Trevena's Olinvo

FDA approved products from Coherus Biosciences Inc. (NASDAQ:CHRS), AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX) and Pfizer Inc. (NYSE:PFE) on Friday, but issued a complete response letter to an NDA from Trevena Inc. (NASDAQ:TRVN). Coherus was up $0.70...